U.S. panel to consider approval of Roche's Actemra in July

06/5/2008 | Reuters

The FDA's Arthritis Advisory Committee is scheduled on July 29 to review Roche Holding's Actemra for approval. The company believes that the drug, which has been approved in Japan, will gain competitive advantage as an alternative to anti-tumor necrosis factor drugs used in rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA